Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $38
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $32 to $38.
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $32 to $38.